mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2023-14-4-108-113mvjr-1796Research ArticleВНУТРЕННИЕ БОЛЕЗНИINTERNAL DISEASESРоль кардиотрофина-1 при хронической сердечной недостаточностиThe role of cardiotrophin-1 in chronic heart failurehttps://orcid.org/0000-0002-4021-325XПахноваЛ. Р.PakhnovaL. R.

Пахнова Лия Руслановна – к.м.н., ассистент кафедры лучевой диагностики

Астрахань

Liya R. Pakhnova – Cand. Sci (Med.), Assistant of the Department of Radiation Diagnostics

Astrakhan

pahnova@mail.ruhttps://orcid.org/0000-0003-4168-4851БашкинаО. А.BashkinaO. A.

Башкина Ольга Александровна – д.м.н, профессор, ректор, заведующая кафедрой факультетской педиатрии

Астрахань

Olga A. Bashkina – Dr. Sci. (Med.), Professor, Rector, Head of the Department of Faculty Pediatrics

Astrakhan

bashkina1@mail.ruhttps://orcid.org/0000-0002-2395-745XВоронинаЛ. П.VoroninaL. P.

Воронина Людмила Петровна – д.м.н., профессор, заведующая кафедрой клинической иммунологии с курсом последипломного образования

Астрахань

Lyudmila P. Voronina – Dr. Sci. (Med.), Professor, Head of the Department of Department of Clinical Immunology with a Postgraduate Course

Astrakhan

voroninaluda74@mail.ruАстраханский государственный медицинский университетРоссияAstrakhan State Medical UniversityRussian Federation202309112023144108113Copyright © Пахнова Л.Р., Башкина О.А., Воронина Л.П., 20232023Пахнова Л.Р., Башкина О.А., Воронина Л.П.Pakhnova L.R., Bashkina O.A., Voronina L.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/1796

Проведён анализ литературных данных, посвящённых роли белка кардиотрофин-1 при хронической сердечной недостаточности. Были отобраны и проанализированы статьи в базах PubMed, ScienceDirect, ProQuest, GoogleScholar, Cochrane, Medline, AMED, EMBASE, CINHAL, SportDiscus, Scopus и PEDro. Поиск статей осуществлён по ключевым словам «Heart failure», «Biological markers», «Cardiotrophin-1», «Galectin-3», «Myocardium» и их комбинациям. Критерии включения – дата публикации с 2017 по 2022 гг., клинические исследования, метаанализы и систематические обзоры, рандомизированные контролируемые исследования, наличие полного текста в открытом доступе либо абстракта. Критерии исключения – тезисы, монографии, учебные пособия, дата публикации до 2017 г., несоответствие тематики исследования, всего 80 публикаций, в обзор включена 21. Представлена информация о роли кардиотрофина-1 при хронической сердечной недостаточности. Кардиотрофин-1 активируется в сердечных фибробластах и кардиомиоцитах в ответ на механический, гуморальный, метаболический и гипоксический стресс. Данный биомаркер обильно экспрессируется в ткани сердца, его сверхэкспрессия в основном стимулируется растяжением/давлением желудочков, что способствует гипертрофии миокарда. Экспериментальное введение кардиотрофина-1 приводит к фиброзу и ремоделированию миокарда, что указывает на его роль в качестве диагностического биомаркера при данных патологиях и хронической сердечной недостаточности в целом.

An analysis of the literature data on the role of the cardiotrophin-1 protein in chronic heart failure was carried out. Articles were selected and analyzed in PubMed, ScienceDirect, ProQuest, GoogleScholar, Cochrane, Medline, AMED, EMBASE, CINHAL, SportDiscus, Scopus and PEDro databases. The search for articles was carried out using the keywords: «Heart failure», «Biological markers», «Cardiotrophin-1», «Galectin-3», «Myocardium» and their combinations. Inclusion criteria were publication date from 2017 to 2022, clinical studies, meta-analyses and systematic reviews, randomized controlled trials, availability of the full text in the public domain or the abstract. Exclusion criteria: abstracts, monographs, textbooks, publication date before 2017, inconsistency with the research topic. A total of 80 publications were found. The review included 18 publications from 2017 to 2022 that corresponded to the topic and purpose of the study and were significant for revealing the subject of the study. Information is presented on the role of cardiotrophin-1 in chronic heart failure. Cardiotrophin-1 is activated in cardiac fibroblasts and cardiomyocytes in response to mechanical, humoral, metabolic and hypoxic stress. This biomarker is abundantly expressed in cardiac tissue and its overexpression is mainly stimulated by ventricular stretch/pressure, which promotes myocardial hypertrophy. Experimental administration of cardiotrophin-1 leads to fibrosis and myocardial remodeling, which indicates its role as a diagnostic biomarker in these pathologies and chronic heart failure in general.

обзорсердечная недостаточностьбиологические маркерыкардиотрофин-1галектин-3миокардreviewheart failurebiological markerscardiotrophin-1galectin-3myocardiumReferencesLindmark K, Boman K, Olofsson M, Törnblom M, Levine A, et al. Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden. Clin Epidemiol. 2019;11:231-244. https://doi.org/10.2147/CLEP.S170873Lindmark K, Boman K, Olofsson M, Törnblom M, Levine A, et al. Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden. Clin Epidemiol. 2019;11:231-244. https://doi.org/10.2147/CLEP.S170873Agra RM, Fernandez-Trasancos A, Diaz-Rodriguez E, Cordero A, Varela-Román A, et al. Nu-trients restriction upregulates adiponectin in epicardial or subcutaneous adipose tissue: impact in de novo heart failure patients. Int J Med Sci. 2018;15(5):417-424. https://doi.org/10.7150/ijms.22854Agra RM, Fernandez-Trasancos A, Diaz-Rodriguez E, Cordero A, Varela-Román A, et al. Nu-trients restriction upregulates adiponectin in epicardial or subcutaneous adipose tissue: impact in de novo heart failure patients. Int J Med Sci. 2018;15(5):417-424. https://doi.org/10.7150/ijms.22854Frangogiannis NG. The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest. 2017;127(5):1600-1612. https://doi.org/10.1172/JCI87491Frangogiannis NG. The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest. 2017;127(5):1600-1612. https://doi.org/10.1172/JCI87491Ravassa S, López B, Querejeta R, Echegaray K, San José G, et al. Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. J Hypertens. 2017;35(4):853-861. https://doi.org/10.1097/HJH.0000000000001258Ravassa S, López B, Querejeta R, Echegaray K, San José G, et al. Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. J Hypertens. 2017;35(4):853-861. https://doi.org/10.1097/HJH.0000000000001258Поляков Д.С., Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021;61(4):4-14.Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCHCHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.) https://doi.org/10.18087/cardio.2021.4.n1628Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017;135(22):e1054-e1091. Erratum in: Circulation. 2017;136(19):e345. PMID: 28446515. https://doi.org/10.1161/CIR.0000000000000490Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017;135(22):e1054-e1091. Erratum in: Circulation. 2017;136(19):e345. PMID: 28446515. https://doi.org/10.1161/CIR.0000000000000490Ibrahim NE, Januzzi JL Jr. Established and Emerging Roles of Biomarkers in Heart Failure. Circ Res. 2018;123(5):614-629. https://doi.org/10.1161/CIRCRESAHA.118.312706Ibrahim NE, Januzzi JL Jr. Established and Emerging Roles of Biomarkers in Heart Failure. Circ Res. 2018;123(5):614-629. https://doi.org/10.1161/CIRCRESAHA.118.312706Martínez-Martínez E, Brugnolaro C, Ibarrola J, Ravassa S, Buonafine M, et al. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension. 2019;73(3):602-611. https://doi.org/10.1161/HYPERTENSIONAHA.118.11874Martínez-Martínez E, Brugnolaro C, Ibarrola J, Ravassa S, Buonafine M, et al. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension. 2019;73(3):602-611. https://doi.org/10.1161/HYPERTENSIONAHA.118.11874Khosravi F, Ahmadvand N, Wartenberg M, Sauer H. Induction of Stem-Cell-Derived Cardiomyogenesis by Fibroblast Growth Factor 10 (FGF10) and Its Interplay with Cardiotrophin-1 (CT-1). Biology (Basel). 2022;11(4):534. https://doi.org/10.3390/biology11040534Khosravi F, Ahmadvand N, Wartenberg M, Sauer H. Induction of Stem-Cell-Derived Cardiomyogenesis by Fibroblast Growth Factor 10 (FGF10) and Its Interplay with Cardiotrophin-1 (CT-1). Biology (Basel). 2022;11(4):534. https://doi.org/10.3390/biology11040534Hogas S, Bilha SC, Branisteanu D, Hogas M, Gaipov A, et al. Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3. Arch Med Sci. 2017;13(4):897-913. https://doi.org/10.5114/aoms.2016.58664Hogas S, Bilha SC, Branisteanu D, Hogas M, Gaipov A, et al. Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3. Arch Med Sci. 2017;13(4):897-913. https://doi.org/10.5114/aoms.2016.58664Abdul-Ghani M, Suen C, Jiang B, Deng Y, Weldrick JJ, et al. Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart. Cell Res. 2017;27(10):1195-1215. https://doi.org/10.1038/cr.2017.87Abdul-Ghani M, Suen C, Jiang B, Deng Y, Weldrick JJ, et al. Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart. Cell Res. 2017;27(10):1195-1215. https://doi.org/10.1038/cr.2017.87Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356. https://doi.org/10.1002/ejhf.1858Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356. https://doi.org/10.1002/ejhf.1858Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.Circulation. 2018;138(9):861-870. https://doi.org/10.1161/CIRCULATIONAHA.118.034646Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.Circulation. 2018;138(9):861-870. https://doi.org/10.1161/CIRCULATIONAHA.118.034646Sharif S, Saleem A, Naz S, Rashid F, Iqtedar M, et al. Increased Expression of Cardiotrophin-1 in Cardiomyopathy Patients. Balkan J Med Genet. 2021;24(1):21-26. https://doi.org/10.2478/bjmg-2021-0008Sharif S, Saleem A, Naz S, Rashid F, Iqtedar M, et al. Increased Expression of Cardiotrophin-1 in Cardiomyopathy Patients. Balkan J Med Genet. 2021;24(1):21-26. https://doi.org/10.2478/bjmg-2021-0008Vega RB, Konhilas JP, Kelly DP, Leinwand LA. Molecular Mechanisms Underlying Cardiac Adaptation to Exercise. Cell Metab. 2017;25(5):1012-1026. https://doi.org/10.1016/j.cmet.2017.04.025Vega RB, Konhilas JP, Kelly DP, Leinwand LA. Molecular Mechanisms Underlying Cardiac Adaptation to Exercise. Cell Metab. 2017;25(5):1012-1026. https://doi.org/10.1016/j.cmet.2017.04.025Ping Y, Wang X, Dai Y, Wang D, Liu W, et al. A quantitative detection of Cardiotrophin-1 in chronic heart failure by chemiluminescence immunoassay. J Clin Lab Anal. 2021;35(4):e23570. https://doi.org/10.1002/jcla.23570Ping Y, Wang X, Dai Y, Wang D, Liu W, et al. A quantitative detection of Cardiotrophin-1 in chronic heart failure by chemiluminescence immunoassay. J Clin Lab Anal. 2021;35(4):e23570. https://doi.org/10.1002/jcla.23570Ben Aissa A, Herrera-Chacon A, Pupin RR, Sotomayor MDPT, Pividori MI. Magnetic molecularly imprinted polymer for the isolation and detection of biotin and biotinylated biomolecules. Biosens Bioelectron. 2017;88:101-108. https://doi.org/10.1016/j.bios.2016.07.096Ben Aissa A, Herrera-Chacon A, Pupin RR, Sotomayor MDPT, Pividori MI. Magnetic molecularly imprinted polymer for the isolation and detection of biotin and biotinylated biomolecules. Biosens Bioelectron. 2017;88:101-108. https://doi.org/10.1016/j.bios.2016.07.096Gyöngyösi M, Winkler J, Ramos I, Do QT, Firat H, et al. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail. 2017;19(2):177-191. https://doi.org/10.1002/ejhf.696Gyöngyösi M, Winkler J, Ramos I, Do QT, Firat H, et al. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail. 2017;19(2):177-191. https://doi.org/10.1002/ejhf.696Arrieta V, Martinez-Martinez E, Ibarrola J, Alvarez V, Sádaba R, et al. A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis. Clin Sci (Lond). 2017;131(10):935-949. https://doi.org/10.1042/CS20170145Arrieta V, Martinez-Martinez E, Ibarrola J, Alvarez V, Sádaba R, et al. A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis. Clin Sci (Lond). 2017;131(10):935-949. https://doi.org/10.1042/CS20170145Ионин В.А., Барашкова Е.И., Павлова В.А., Борисов Г.И., Аверченко К.А., и др. Какова роль профибротических и провоспалительных факторов в развитии фибрилляции предсердий, ассоциированной с компонентами метаболического синдрома? Российский кардиологический журнал. 2021;26(11):4752.Ionin V.A., Barashkova E.I., Pavlova V.A., Borisov G.I., Averchenko K.A., et al. What is the role of profibrogenic and proinflammatory factors in developing atrial fibrillation associated with metabolic syndrome components? Russian Journal of Cardiology. 2021;26(11):4752. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4752Огуркова О.Н., Павлюкова Е.Н., Суслова Т.Е. Исследование содержания кардиотрофина-1 в сыворотке крови у пациентов с обструктивной гипертрофической кардиомиопатией и пациентов с тяжелой левожелудочковой дисфункцией. Сибирский журнал клинической и экспериментальной медицины. 2021;36(2):70-75.Ogurkova O.N., Pavlyukova E.N., Suslova T.E. Serum levels of cardiotrophin-1 in patients with obstructive hypertrophic cardiomyopathy and in patients with severe left ventricular dysfunction. The Siberian Journal of Clinical and Experimental Medicine. 2021;36(2):70-75. (In Russ.) https://doi.org/10.29001/2073-8552-2021-36-2-70-75

The authors declare that there are no conflicts of interest present.